JAZZ Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is $5.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.1% since its last earnings release on August 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases -- often with limited or no options.
Sector
Healthcare
Industry
Biotechnology